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CASE REPORT 
[3120+1kbdel8.6kb]+[p.N1303K] GENOTYPE IN AN EMIRATI CYSTIC 
FIBROSIS PATIENT: INDICATION OF A FOUNDER MUTATION IN 
PALESTINIAN ARABS 
Danish Saleheen, Philippe M. Frossard, Emmanuelle Girodon 
Department of Biological and Biomedical Sciences, Aga Khan University, Karachi, Pakistan and *Laboratoire de Genetique Moleculaire, 
INSERM U91, Hospital Henri Mondor, Creteil, France. 
Cystic fibrosis (CF) is the most common life-limiting autosomal recessive disorder in Caucasian 
population. The disease was initially considered to be rare in Middle Eastern countries. 95% of CF 
in Emirati families is due to two mutations only – p.S549R(T>G) and p.F508del. We report here 
the case of a patient referred to CF and Respiratory Clinic at Tawam Hospital for cystic fibrosis 
transmembrane regulator (CFTR) gene screening to ascertain the diagnosis of CF, who was found 
to carry a unique genotype, signifying the importance of retrieving ancestral histories of patients 
with monogenic disorders 
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INTRODUCTION 
Cystic fibrosis (CF) is the most common life-limiting 
autosomal recessive disorder in  Caucasian 
population.1 It is a multisystem disorder characterized 
by a constellation of symptoms mainly including 
chronic bacterial infection of airways, pancreatic 
insufficiency, infertility in males and increased 
concentration of chloride in sweat.1 It is caused by 
defect in a 190 kb gene on chromosome 7 encoding a 
1480 amino acid polypeptide, named cystic fibrosis 
transme mbrane regulator (CFTR).1,2 To date 1523 
CFTR gene mutations have been identified, 
responsible for CF or related diseases .3 
Cystic fibrosis occurs in an estimated 1 in 
2500 live births in Caucasians.1 However its 
incidence is quite variable, and ranges fro m 1/500 in 
Ohio Amish to 1/90000 in Hawaiian Orientals .1 The 
disease was initially considered to be rare in Middle 
Eastern countries.4 However better awareness and 
improved diagnostic tools have suggested a higher 
incidence.5 Since the startup of the first Cystic 
Fibrosis and Respiratory Clinic at Tawam hospital, 
Al Ain, U.A.E. in 1995, there has been an increased 
awareness on cystic fibrosis among general 
practitioners and pediatricians in the region.6 In a 
study aimed at identifying the mutations responsible 
for the disease in the Emirati population, it was found 
that the pattern of CF-causing mutations is different 
in this population as compared to the other Arab 
populations in the region.5-6 Indeed, 95% of CF in 
Emirati families is due to two mutations only – 
p.S549R(T>G) and p.F508del.5 We report here the 
case of a patient referred to CF and Respiratory 
Clinic at Tawam Hospital for CFTR  gene screening 
to ascertain the diagnosis of CF, who was found to 
carry a particular genotype. 
CASE REPORT 
The proband is a boy who was referred at 2 months 
of age. He was born to a non-consanguineous healthy 
couple by normal vaginal delivery. Birth weight was 
3.85 kg. He was first referred with respiratory 
distress and poor feeding. During the workup of the 
infant in the ward, his  respiratory tract showed 
colonization of micro-organisms including 
Stenotrophomonas maltophilia and Pseudomonas 
aeruginosa . His condition deteriorated and he was 
transferred to intensive care unit for assisted 
respiration for five days. Abdominal X-rays showed 
wide spread calcifications suggestive of meconium 
peritonitis. The patient was administered intravenous 
antibiotic therapy and his condition gradually 
improved. Sweat chloride concentration was 
100mmol/L. He was also found to be pancreatic 
insufficient based on the presence of steatorrhea and 
measurement of stool chymotrypsin activity which 
was done as described previously.7 Presence of 
Pseudomonas aeruginosa in the respiratory tract, 
meconium peritonitis, high sweat chloride values and 
pancreatic insufficiency, all point towards cystic 
fibrosis and thus a genetic confirmation was done by 
CFTR gene analysis. 
CFTR gene analysis  
The protocol for CFTR gene screening was approved 
by the Research Ethics Committee of the Faculty of 
Medicine and Health Sciences, UAE University, Al 
Ain, UAE. A blood sample was collected and DNA 
was extracted from leukocytes using a reference 
phenol-chloroform protocol. The two most common 
mutations (p.S549R(T>G) and p.F508del) were 
initially screened as described previously,5 but were 
not found. Thirty-one most frequent mutations were 
further screened using the CF assay (Abbot, Rungis, 
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France): the p.N1303K mutation was found on one 
allele. The search for a second mutation was then 
initiated using denaturing gradient gel electrophoresis 
(DGGE) focused on the 27 coding regions8-9: no 
additional mutation could be identified. One of the 
parents forefathers being from Palestine, we further 
screened for a large deletion removing exons 17a to 
18, 3120+1kbdel8.6kb, which has been found 
frequent in Palestinian Arab CF patients and 
proposed as a founder mutation amongst Palestinian 
Arabs.10-11 The boy was heterozygous for this 
deletion, thus carrying the 
[3120+1kbdel8.6kb]+[p.N1303K] genotype. 
DISCUSSION 
So far, it has been observed that mutations p.F508del 
and p.S549R(T>G) account for 88% of chromosomes 
in UAE and explain 95% of CF in Emirati families, 
almost all the reported CF patients being 
homozygous for either of the two mutations.5 
Moreover, the clinical phenotypes associated with 
both mutations were homogeneous and extremely 
severe, including dramatic losses of pulmonary 
function. 
The patient described harboring the large 
3120+1kbdel8.6kb deletion in the CFTR gene is 
unique and further documents the hypothesis of a 
founding effect of this mutation in Palestinian Arabs. 
3120+1kbdel8.6kb was first identified by Lerer et 
al.10 in four Palestinian patients. The mutation causes 
a deletion of exons 17a, 17b and 18. This is one of 
the few large deletions that have been described in 
the CFTR gene.3 This mutation causes an in-frame 
deletion of 160 amino acids that are part of 
transmembrane domains 10-12 of the CFTR 
protein.10 This mutation was later found to have a 
13% prevalence in Palestinian Arabs.11 Patients with 
both a homozygous state and a compound 
heterozygous state for this mutation have been 
reported with a severe phenotype.10-11 The intragenic 
haplotype and the flanking markers were identical in 
all the chromosomes bearing the deletion in the four 
Arabs reported, indicating that this mutation is an 
ancient founder mutation.10 The linked haplotype 
could not be determined in our case, as the parents 
were not available.  
The other mutation found in this patient, 
p.N1303K, was first described by Osborne et al. in 
1991.12 Genotype-phenotype correlations clearly 
indicate that this mutation is severe with respect to 
pancreas status but conclusions on its effect on lung 
disease vary  among studies.13-14 The frequency of 
this mutation is variable among populations. It was 
indeed identified in homozygosity in eight 
Palestinian Arab CF patients, and accounted for 21% 
CF alleles in this population.10  
The fact that the compound CFTR genotype 
[3120+1kbdel8.6kb]+[p.N1303K] is observed in this 
patient of Palestinian ancestry, together with the 
consideration that the deletion has only been 
described in Palestinian Arabs so far, further 
documents the hypothesis that 3120+1kbdel8.6kb is a 
founder mutation in Palestinian Arabs. This case 
report also emphasizes the importance of retrieving 
ancestral histories of patients with monogenic 
disorders, and especially in the case of CF, a disease 
in which patterns of CFTR mutations vary greatly 
among populations. 
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